imipramine ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
substances of the imipramine group 1427 50-49-7

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • imipramine
  • prazepine
  • melipramine
  • imipramine hydrochloride
  • imipramine pamoate
  • imipramine HCl
The prototypical tricyclic antidepressant. It has been used in major depression, dysthymia, bipolar depression, attention-deficit disorders, agoraphobia, and panic disorders. It has less sedative effect than some other members of this therapeutic group.
  • Molecular weight: 280.42
  • Formula: C19H24N2
  • CLOGP: 5.04
  • LIPINSKI: 1
  • HAC: 2
  • HDO: 0
  • TPSA: 6.48
  • ALOGS: -3.63
  • ROTB: 4

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.10 g O
0.10 g P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 1.50 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 5.09 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 42 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 12 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 13 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.08 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 16 hours Lombardo F, Berellini G, Obach RS
S (Water solubility) 50 mg/mL Bocci G, Oprea TI, Benet LZ

Approvals:

DateAgencyCompanyOrphan
April 16, 1959 FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Paranoia 67.85 18.91 25 3385 11654 63473958
Hallucination, auditory 65.57 18.91 25 3385 12799 63472813
Completed suicide 64.37 18.91 57 3353 145616 63339996
Psychotic disorder 51.79 18.91 26 3384 25686 63459926
Toxicity to various agents 45.62 18.91 61 3349 247189 63238423
Stress cardiomyopathy 36.33 18.91 15 3395 9435 63476177
Procedural hypotension 30.71 18.91 8 3402 1182 63484430
Skin hyperpigmentation 28.31 18.91 11 3399 5910 63479702
Iris hyperpigmentation 25.65 18.91 4 3406 41 63485571
Urinary hesitation 21.39 18.91 7 3403 2293 63483319
Decreased activity 20.85 18.91 9 3401 6311 63479301
Limb mass 19.06 18.91 7 3403 3225 63482387

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Blepharospasm 57.32 24.72 13 1789 1125 34954004
Toxicity to various agents 56.59 24.72 60 1742 200302 34754827
Completed suicide 50.20 24.72 41 1761 98127 34857002
Long QT syndrome 45.68 24.72 13 1789 2790 34952339
Neuroleptic malignant syndrome 42.51 24.72 20 1782 17914 34937215
Pyelitis 42.36 24.72 7 1795 111 34955018
Muscle rigidity 38.76 24.72 16 1786 10502 34944627
Dystonia 38.29 24.72 16 1786 10829 34944300
Trismus 38.10 24.72 11 1791 2484 34952645
Delusion 26.61 24.72 13 1789 12622 34942507
Brain oedema 25.51 24.72 13 1789 13808 34941321

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Completed suicide 103.13 18.10 97 4577 245670 79494044
Toxicity to various agents 65.13 18.10 100 4574 421440 79318274
Paranoia 62.88 18.10 28 4646 19404 79720310
Neuroleptic malignant syndrome 59.35 18.10 30 4644 27529 79712185
Hallucination, auditory 48.91 18.10 24 4650 20669 79719045
Overdose 45.55 18.10 55 4619 184151 79555563
Psychotic disorder 38.15 18.10 26 4648 41376 79698338
Blepharospasm 34.62 18.10 13 4661 5838 79733876
Long QT syndrome 34.39 18.10 13 4661 5942 79733772
Pyelitis 34.00 18.10 7 4667 336 79739378
Stress cardiomyopathy 32.66 18.10 15 4659 11151 79728563
Dystonia 28.59 18.10 17 4657 21382 79718332
Trismus 28.23 18.10 11 4663 5456 79734258
Procedural hypotension 25.82 18.10 8 4666 2015 79737699
Skin hyperpigmentation 25.15 18.10 11 4663 7292 79732422
Muscle rigidity 24.51 18.10 15 4659 19867 79719847
Electrocardiogram QT prolonged 23.97 18.10 28 4646 90358 79649356
Respiratory depression 22.29 18.10 16 4658 27614 79712100
Drug interaction 20.47 18.10 62 4612 415121 79324593
Withdrawal syndrome 20.41 18.10 15 4659 26839 79712875
Suicide attempt 19.22 18.10 24 4650 82908 79656806
Parkinsonism 19.14 18.10 12 4662 16572 79723142
Electrocardiogram abnormal 19.04 18.10 12 4662 16725 79722989
Iris hyperpigmentation 18.95 18.10 3 4671 31 79739683
Speech disorder 18.12 18.10 19 4655 54426 79685288

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC N06AA02 NERVOUS SYSTEM
PSYCHOANALEPTICS
ANTIDEPRESSANTS
Non-selective monoamine reuptake inhibitors
MeSH PA D018663 Adrenergic Agents
MeSH PA D018759 Adrenergic Uptake Inhibitors
MeSH PA D000928 Antidepressive Agents
MeSH PA D000929 Antidepressive Agents, Tricyclic
MeSH PA D002491 Central Nervous System Agents
MeSH PA D049990 Membrane Transport Modulators
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D014179 Neurotransmitter Uptake Inhibitors
MeSH PA D011619 Psychotropic Drugs
CHEBI has role CHEBI:35469 antidepressants
FDA EPC N0000175752 Tricyclic Antidepressant
CHEBI has role CHEBI:35640 adrenergic uptake inhibitors
CHEBI has role CHEBI:76779 post-proline endopeptidase inhibitors

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Nocturnal enuresis indication 8009008
Depressive disorder indication 35489007
Neuralgia off-label use 16269008
Cataplexy off-label use 46263000
Anxiety off-label use 48694002
Narcolepsy off-label use 60380001 DOID:8986
Bulimia nervosa off-label use 78004001
Neuropathic pain off-label use 247398009
Panic disorder off-label use 371631005 DOID:594
Attention deficit hyperactivity disorder off-label use 406506008
Ocular hypertension contraindication 4210003 DOID:9282
Suicidal thoughts contraindication 6471006
Alcoholism contraindication 7200002
Bipolar disorder contraindication 13746004 DOID:3312
Electroconvulsive therapy contraindication 23835007
Alcohol intoxication contraindication 25702006
Hyperthyroidism contraindication 34486009 DOID:7998
Conduction disorder of the heart contraindication 44808001
Chronic heart failure contraindication 48447003
Disorder of cardiovascular system contraindication 49601007 DOID:1287
Paralytic ileus contraindication 55525008 DOID:8442
Schizophrenia contraindication 58214004 DOID:5419
Intestinal obstruction contraindication 81060008 DOID:8437
Epilepsy contraindication 84757009 DOID:1826
Kidney disease contraindication 90708001 DOID:557
Seizure disorder contraindication 128613002
Cerebrovascular accident contraindication 230690007
Mania contraindication 231494001
Hypomania contraindication 231496004
Disease of liver contraindication 235856003 DOID:409
Benign prostatic hyperplasia contraindication 266569009
Retention of urine contraindication 267064002
Syncope contraindication 271594007
Thrombocytopenic disorder contraindication 302215000 DOID:1588
Neutropenic disorder contraindication 303011007 DOID:1227
Surgical procedure contraindication 387713003
Angle-closure glaucoma contraindication 392291006 DOID:13550
Disorder of coronary artery contraindication 414024009
Myocardial infarction in recovery phase contraindication 418044006




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 9.04 Basic
pKa2 5.01 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Sodium-dependent noradrenaline transporter Transporter INHIBITOR Kd 7.43 WOMBAT-PK CHEMBL
Sodium-dependent serotonin transporter Transporter INHIBITOR Kd 8.85 WOMBAT-PK CHEMBL
Potassium voltage-gated channel subfamily H member 2 Ion channel IC50 5.90 WOMBAT-PK
5-hydroxytryptamine receptor 1A GPCR Ki 5.24 PDSP
5-hydroxytryptamine receptor 2A GPCR Ki 6.83 WOMBAT-PK
5-hydroxytryptamine receptor 2C GPCR Ki 6.80 WOMBAT-PK
Alpha-1A adrenergic receptor GPCR IC50 7.50 WOMBAT-PK
Alpha-2B adrenergic receptor GPCR IC50 7.10 WOMBAT-PK
D(3) dopamine receptor GPCR Ki 6.41 WOMBAT-PK
Histamine H1 receptor GPCR IC50 7.61 WOMBAT-PK
Muscarinic acetylcholine receptor M1 GPCR Ki 7.38 WOMBAT-PK
Muscarinic acetylcholine receptor M2 GPCR Ki 8.08 WOMBAT-PK
Muscarinic acetylcholine receptor M3 GPCR Ki 7.22 WOMBAT-PK
Muscarinic acetylcholine receptor M4 GPCR Ki 6.95 WOMBAT-PK
Muscarinic acetylcholine receptor M5 GPCR Ki 7.08 WOMBAT-PK
Sodium-dependent dopamine transporter Transporter Ki 5.07 PDSP
Adenosine receptor A3 GPCR IC50 8.36 CHEMBL
Voltage-dependent N-type calcium channel subunit alpha-1B Ion channel IC50 4.66 CHEMBL
Major prion protein Surface antigen EC50 5 CHEMBL
Solute carrier family 22 member 1 Transporter IC50 4.77 CHEMBL
Potassium voltage-gated channel subfamily H member 1 Ion channel BLOCKER IC50 5.70 IUPHAR
Solute carrier family 22 member 2 Transporter IC50 5.22 WOMBAT-PK
Sodium channel alpha subunits; brain (Types I, II, III) Ion channel IC50 5.44 CHEMBL
Sphingomyelin phosphodiesterase Enzyme IC50 5.30 CHEMBL
D(2) dopamine receptor GPCR Ki 6.17 WOMBAT-PK
Sigma non-opioid intracellular receptor 1 Membrane receptor Ki 6.28 WOMBAT-PK
Alpha-1A adrenergic receptor GPCR IC50 8.77 CHEMBL
Sodium-dependent serotonin transporter Transporter Ki 7.38 CHEMBL
Sigma non-opioid intracellular receptor 1 Membrane receptor Ki 6.46 CHEMBL
Transporter Transporter Ki 7.92 CHEMBL
Sodium-dependent dopamine transporter Transporter Ki 7.38 CHEMBL
Sodium-dependent noradrenaline transporter Transporter Ki 7.92 CHEMBL
5-hydroxytryptamine receptor 2C GPCR Ki 6.80 CHEMBL
D(2) dopamine receptor GPCR Ki 6.14 CHEMBL
Sodium-dependent serotonin transporter Transporter Ki 8.30 CHEMBL
Histamine H1 receptor GPCR IC50 10.22 CHEMBL
Muscarinic acetylcholine receptor M5 GPCR IC50 6.52 CHEMBL
Pleiotropic ABC efflux transporter of multiple drugs Transporter IC50 4.66 CHEMBL
Glutamate NMDA receptor Ion channel IC50 4.85 CHEMBL
Muscarinic acetylcholine receptor GPCR Ki 7.19 CHEMBL
Serotonin (5-HT) receptor GPCR IC50 7.36 CHEMBL
Adrenergic receptor alpha-2 GPCR Ki 6.59 CHEMBL
Dopamine receptor GPCR IC50 6.19 CHEMBL
Adrenergic receptor alpha-1 GPCR Ki 7.34 CHEMBL
Serotonin 2 (5-HT2) receptor GPCR Ki 7.64 CHEMBL
G protein-activated inward rectifier potassium channel 4 Ion channel BLOCKER EC50 4.50 IUPHAR
G protein-activated inward rectifier potassium channel 2 Ion channel BLOCKER IC50 4.30 IUPHAR
Sigma intracellular receptor 2 Unclassified Ki 5.68 CHEMBL

External reference:

IDSource
4019785 VUID
N0000147875 NUI
D00815 KEGG_DRUG
73-07-4 SECONDARY_CAS_RN
113-52-0 SECONDARY_CAS_RN
10075-24-8 SECONDARY_CAS_RN
4017862 VANDF
4017863 VANDF
4019785 VANDF
C0020934 UMLSCUI
CHEBI:47499 CHEBI
IXX PDB_CHEM_ID
CHEMBL11 ChEMBL_ID
DB00458 DRUGBANK_ID
CHEMBL2105257 ChEMBL_ID
CHEMBL1692 ChEMBL_ID
CHEMBL3989845 ChEMBL_ID
D007099 MESH_DESCRIPTOR_UI
3696 PUBCHEM_CID
357 IUPHAR_LIGAND_ID
793 INN_ID
OGG85SX4E4 UNII
150816 RXNORM
2328 MMSL
4870 MMSL
4871 MMSL
81685 MMSL
d00259 MMSL
001498 NDDF
001499 NDDF
001500 NDDF
3378009 SNOMEDCT_US
36113004 SNOMEDCT_US
372718005 SNOMEDCT_US
4203009 SNOMEDCT_US
1916 INN_ID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Imipramine Pamoate HUMAN PRESCRIPTION DRUG LABEL 1 0054-0273 CAPSULE 75 mg ORAL ANDA 20 sections
Imipramine Pamoate HUMAN PRESCRIPTION DRUG LABEL 1 0054-0273 CAPSULE 75 mg ORAL ANDA 20 sections
Imipramine Pamoate HUMAN PRESCRIPTION DRUG LABEL 1 0054-0274 CAPSULE 100 mg ORAL ANDA 20 sections
Imipramine Pamoate HUMAN PRESCRIPTION DRUG LABEL 1 0054-0274 CAPSULE 100 mg ORAL ANDA 20 sections
Imipramine Pamoate HUMAN PRESCRIPTION DRUG LABEL 1 0054-0275 CAPSULE 125 mg ORAL ANDA 20 sections
Imipramine Pamoate HUMAN PRESCRIPTION DRUG LABEL 1 0054-0275 CAPSULE 125 mg ORAL ANDA 20 sections
Imipramine Pamoate HUMAN PRESCRIPTION DRUG LABEL 1 0054-0276 CAPSULE 150 mg ORAL ANDA 20 sections
Imipramine Pamoate HUMAN PRESCRIPTION DRUG LABEL 1 0054-0276 CAPSULE 150 mg ORAL ANDA 20 sections
Imipramine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0781-1762 TABLET, FILM COATED 10 mg ORAL ANDA 19 sections
Imipramine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0781-1764 TABLET, FILM COATED 25 mg ORAL ANDA 19 sections
Imipramine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0781-1766 TABLET, FILM COATED 50 mg ORAL ANDA 19 sections
IMIPRAMINE PAMOATE HUMAN PRESCRIPTION DRUG LABEL 1 16590-963 CAPSULE 75 mg ORAL NDA 22 sections
Imipramine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 42291-345 TABLET, FILM COATED 10 mg ORAL ANDA 24 sections
Imipramine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 42291-346 TABLET, FILM COATED 25 mg ORAL ANDA 24 sections
Imipramine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 42291-347 TABLET, FILM COATED 50 mg ORAL ANDA 24 sections
Imipramine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 49884-054 TABLET 10 mg ORAL ANDA 20 sections
Imipramine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 49884-055 TABLET 25 mg ORAL ANDA 20 sections
Imipramine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 49884-056 TABLET 50 mg ORAL ANDA 20 sections
Imipramine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 50090-0035 TABLET, FILM COATED 25 mg ORAL ANDA 21 sections
Imipramine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 50090-3148 TABLET, FILM COATED 25 mg ORAL ANDA 21 sections
Imipramine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 50090-3148 TABLET, FILM COATED 25 mg ORAL ANDA 21 sections
Imipramine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 50436-2022 TABLET, FILM COATED 25 mg ORAL ANDA 21 sections
IMIPRAMINE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 51655-455 TABLET, FILM COATED 50 mg ORAL ANDA 12 sections
Imipramine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 54868-1344 TABLET, FILM COATED 25 mg ORAL ANDA 20 sections
Imipramine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 54868-2221 TABLET, FILM COATED 50 mg ORAL ANDA 20 sections
Imipramine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 54868-2571 TABLET, FILM COATED 10 mg ORAL ANDA 20 sections
Imipramine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 55289-144 TABLET, FILM COATED 25 mg ORAL ANDA 19 sections
Imipramine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 55700-709 TABLET, FILM COATED 10 mg ORAL ANDA 20 sections
Imipramine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 55700-709 TABLET, FILM COATED 10 mg ORAL ANDA 20 sections
Imipramine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 55700-710 TABLET, FILM COATED 25 mg ORAL ANDA 20 sections